Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Genitourinary Cancer
Watch Time: 5 mins

Morgan Rouprêt, ESOU22: Impact of Immune Checkpoint Inhibitors on the Treatment of Bladder, Prostate and Kidney Cancer

Copy Link
Published Online: Feb 18th 2022

touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss the impact of immune checkpoint inhibitors on the treatment of bladder cancer, and other exciting therapeutic advances.

Questions

  1.       How have immune checkpoint inhibitors changed the treatment landscape for bladder cancer? (00:35-03:35)
  2.       What are the most exciting recent and emerging therapeutic advances in bladder cancer? (03:35-05:05)

Speaker Disclosure: Morgan Rouprêt has no conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the EAU Section of Oncological Urology (ESOU) 2022 conference.

Share this Video
Related Videos In Genitourinary Cancer
Genitourinary Cancer
Developed by Touch
Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?
Watch Time: 5 mins

Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, discusses what he hopes to see in the field of uro-oncological surgery in the next five years. He hopes this will include improving early detection of prostate cancer and therefore the possibility of avoiding surgery; improving prognostic factors and diagnosis in early disease […]

Genitourinary Cancer
Developed by Touch
Arnulf Stenzl, EAU23: Latest developments in urological oncology
Watch Time: 10 mins

It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Minimalise any uro-oncologic surgery, more precise, complete removal of tumour, improving outcomes (00:37) Developments in robot-assisted surgery […]

Genitourinary Cancer
Developed by Touch
Arnulf Stenzl: Pivotal new projects of the European Association of Urology (EAU)
Watch Time: 8 mins

It was a pleasure to hear from the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the pivotal new projects and initiatives the society are currently working on. Topics covered Meetings and introducing more virtual, web-based education post-COVID (00:20) Projects, real-world data, future strategies (3:30) Development of […]

Trending In Genitourinary Cancer:

Looking to the future with Arnulf Stenzl: What can we hope to see in urological oncology in the next 5 years?
Genitourinary Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72